Vertex Pharmaceuticals Inc Total Liabilities
Vertex Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Vertex Pharmaceuticals Inc (VRTX) has total liabilities worth $7.18 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check VRTX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Vertex Pharmaceuticals Inc (1990–2025)
Total liabilities of Vertex Pharmaceuticals Inc from 1990 to 2025. This chart illustrates how Vertex Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Vertex Pharmaceuticals Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Vertex Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Vertex Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Merchants Bank Co Ltd
SHG:600036
|
China | CN¥11.36 Trillion |
|
Eaton Corporation PLC
F:3EC
|
Germany | €35.32 Billion |
|
Anheuser Busch Inbev SA NV
BR:ABI
|
Belgium | €121.09 Billion |
|
Iberdrola S.A.
MC:IBE
|
Spain | €97.34 Billion |
|
Foxconn Industrial Internet Co Ltd
SHG:601138
|
China | CN¥336.65 Billion |
|
Deutsche Telekom AG
F:DTEA
|
Germany | €202.56 Billion |
|
Bristol-Myers Squibb Company
NYSE:BMY
|
USA | $65.31 Billion |
|
ABB Ltd
SW:ABBN
|
Switzerland | CHF28.24 Billion |
Liability Composition Analysis (1990–2025)
This chart breaks down Vertex Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see VRTX current and non-current assets.
Liquidity & Leverage Metrics
Vertex Pharmaceuticals Inc Total Liabilities Ratios Explained
Vertex Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vertex Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vertex Pharmaceuticals Inc (1990–2025)
The table below shows the annual total liabilities of Vertex Pharmaceuticals Inc from 1990 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.48 Billion | +22.10% |
| 2024-12-31 | $6.12 Billion | +18.91% |
| 2023-12-31 | $5.15 Billion | +21.51% |
| 2022-12-31 | $4.24 Billion | +27.18% |
| 2021-12-31 | $3.33 Billion | +8.73% |
| 2020-12-31 | $3.06 Billion | +37.25% |
| 2019-12-31 | $2.23 Billion | +23.34% |
| 2018-12-31 | $1.81 Billion | +20.42% |
| 2017-12-31 | $1.50 Billion | -3.34% |
| 2016-12-31 | $1.56 Billion | +10.77% |
| 2015-12-31 | $1.40 Billion | +13.39% |
| 2014-12-31 | $1.24 Billion | +28.66% |
| 2013-12-31 | $962.64 Million | -36.87% |
| 2012-12-31 | $1.52 Billion | +23.10% |
| 2011-12-31 | $1.24 Billion | +1.42% |
| 2010-12-31 | $1.22 Billion | +42.17% |
| 2009-12-31 | $859.14 Million | +15.85% |
| 2008-12-31 | $741.61 Million | +124.60% |
| 2007-12-31 | $330.18 Million | -20.56% |
| 2006-12-31 | $415.64 Million | +34.16% |
| 2005-12-31 | $309.82 Million | -39.25% |
| 2004-12-31 | $510.01 Million | -4.05% |
| 2003-12-31 | $531.57 Million | +21.60% |
| 2002-12-31 | $437.14 Million | -2.81% |
| 2001-12-31 | $449.78 Million | +5.30% |
| 2000-12-31 | $427.12 Million | +1740.18% |
| 1999-12-31 | $23.21 Million | +15.48% |
| 1998-12-31 | $20.10 Million | +2.55% |
| 1997-12-31 | $19.60 Million | +54.33% |
| 1996-12-31 | $12.70 Million | -7.30% |
| 1995-12-31 | $13.70 Million | +28.04% |
| 1994-12-31 | $10.70 Million | -6.96% |
| 1993-12-31 | $11.50 Million | +61.97% |
| 1992-12-31 | $7.10 Million | +44.90% |
| 1991-12-31 | $4.90 Million | +22.50% |
| 1990-12-31 | $4.00 Million | -- |
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with C… Read more